Novo Nordisk adds pediatric data to bulging bag of evidence on near-approval hemophilia A prospect

Novo Nordisk has bolstered the case for its near-approval hemophilia A drug candidate Mim8, linking the prospect to reductions in treated bleeds in children with the hereditary bleeding disorder.